Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Polyrizon Ltd. ( (PLRZ) ) has provided an announcement.
On January 22, 2026, Polyrizon Ltd. announced it has initiated a key human factors usability study program for NASARIX™, its lead intranasal allergy blocker designed for broad consumer use, marking an important milestone on its development and regulatory path. The study, structured to align with U.S. Food and Drug Administration (FDA) human factors and usability engineering guidance, focuses on critical elements such as labeling, instructions for use and user interaction, with the aim of de-risking future regulatory review and providing evidence to support NASARIX™ readiness for clinical evaluation; successful completion is expected to support the company’s plan to begin clinical trials in the third quarter of 2026 and could strengthen Polyrizon’s positioning as it advances toward potential commercialization in the intranasal allergy protection market.
More about Polyrizon Ltd.
Polyrizon Ltd. is a development-stage biotechnology company specializing in innovative intranasal medical device hydrogels delivered as nasal sprays. Its proprietary Capture and Contain (C&C) hydrogel technology forms a thin “biological mask” barrier in the nasal cavity to help protect against viruses and allergens, while the company is also advancing earlier-stage Trap and Target (T&T) technology aimed at intranasal delivery of active pharmaceutical ingredients for therapeutic applications.
Average Trading Volume: 3,204,098
Technical Sentiment Signal: Sell
Current Market Cap: $23.26M
Learn more about PLRZ stock on TipRanks’ Stock Analysis page.